In this brief, we discuss the introduction of interchangeable biosimilars, a generic form of biologics, as well as efforts to encourage their use, particularly in the Medicare program.
Using claims data before and during the COVID-19 pandemic (2017–21), this analysis examined skilled nursing facility (SNF) admissions among Medicare fee-for-service beneficiaries who were dually eligible for Medicare and Medicaid and beneficiaries who were eligible only for Medicare.